Optogenetics: implications for Alzheimer’s disease research and therapy

Parsa Mirzayi1,2, Parnian Shobeiri1,2,3, Amirali Kalantari1,2, George Perry5 and Nima Rezaei2,4,6,7*

Abstract
Alzheimer’s disease (AD), a critical neurodegenerative condition, has a wide range of effects on brain activity. Synaptic plasticity and neuronal circuits are the most vulnerable in Alzheimer’s disease, but the exact mechanism is unknown. Incorporating optogenetics into the study of AD has resulted in a significant leap in this field during the last decades, kicking off a revolution in our knowledge of the networks that underpin cognitive functions. In Alzheimer’s disease, optogenetics can help to reduce and reverse neural circuit and memory impairments. Here we review how optogenetically driven methods have helped expand our knowledge of Alzheimer’s disease, and how optogenetic interventions hint at a future translation into therapeutic possibilities for further utilization in clinical settings. In conclusion, neuroscience has witnessed one of its largest revolutions following the introduction of optogenetics into the field.

Keywords: Alzheimer’s disease, Optogenetics, Neural circuits, Neurodegeneration, Synapse, Molecular pathways, Memory

Introduction
“A peculiar severe disease process of the cerebral cortex” are the words used by A. Alzheimer to describe his patient’s severe memory loss, personality changes, and sleep disturbance in 1906. This condition is now known as Alzheimer’s disease (AD), the world’s leading cause of dementia, the most common neurodegenerative disease, and the 5th overall cause of mortality affecting ~44 million people globally [1]. At the same time, even though several theories for AD etiology have emerged throughout the past century, its etiology and pathology remain relatively unclear, and no successful treatment exists [2].

Francis Crick once suggested that the main challenge facing neuroscience is to control one cell type in the brain while leaving others untouched [3]. The remarkable specificity of optogenetic techniques, first introduced in 2005 by a pair of researchers [4, 5], has allowed scientists to address this issue. Researches can now target very specific populations of cells within (or sometimes across) tissues and observe neural networks in a much higher resolution [6, 7], helping to better dissect the pathology behind several neurologic conditions [8]. Optogenetics is using genetically modified cells expressing proteins that respond to light [9]. This method has been an important milestone in neuroscience, aiding researchers in discovering and modulating neural circuits that govern different complex functions of behavior and cognition [10–13]. Optogenetic findings can determine dependencies and infer causality, which is necessary for establishing circuit-centric therapeutics, thus overcoming the limitations of most other approaches [14].

Here we review recent breakthroughs in AD research and discuss what the future clinical horizon looks like. Although optogenetics has had broad uses in neuroscience studies, we have only chosen studies that have been used on AD models or have clear implications for understanding or treating AD.
Introduction to optogenetic methods

Opsins
Rhodopsins (named for their light-responsive molecule opsin), first reported in 1971 [15], are light-sensitive proteins that are expressed in all organisms [16]. These transmembrane proteins respond to different wavelengths of electromagnetic light, thus initiating ion exchanges that alter the plasma membrane potential. The central idea behind optogenetics is fine-tuning these proteins to fit into specific subpopulations of cells and then inducing said membrane potential changes using light [17].

Optogenetics studies commonly use microbial opsins because of their efficient kinetics and that they are relatively simpler to engineer [18]. These including ion pumps (such as bacteriorhodopsins and halorhodopsins) and ion channels (such as channelrhodopsins) [19]. Opsins have been rigorously engineered to offer a complex toolbox for neuronal excitation or inhibition, as well as control of intracellular signaling [20, 21], rendering optogenetics a powerful method to modulate molecular events in a targeted manner.

Gene vehicles
Opsin-encoding genes must be delivered into the desired cell population, and various delivery methods exist for this purpose. Lentiviral and adeno-associated viral vectors are most commonly used to transfer the opsin gene into the desired cell population [13, 17]. Viruses allow the simultaneous induction of activation or inhibition in neural cells of the same class, even if scattered throughout the tissue and offer an extraordinary efficacy in invading living cells [4]. Non-viral vectors are also being explored; these vehicles are safer, cost-effective, and relatively easier to use; but have lower delivery efficacy and expression rates [22].

Light delivery
The main methods of introducing light into the tissue are (1) distant light sources that require infiltration of the tissue, typically through an optical fiber, and (2) in-site light sources (such as LEDs), which can either be implanted [23] or directly target the cortical surface [24, 25]. LEDs and lasers are widely used due to their simplicity, effectiveness, and cost. Their disadvantage is having a narrow spectral bandwidth requiring two different devices to activate two spectrally different opsins independently [26].

Optical fibers can potentially be connected to any light source as long as their power is controlled. This control is necessary so that the tissue is exposed to as little light as possible to minimize heat and light damage, but also sufficient light to activate the opsins. Standard white light sources work in this setting, but given that light should be band-passed to reduce the power and opsins have different sensitivities to wavelengths, the right filter should be applied [27].

Role of optogenetics in revealing Alzheimer’s disease pathogenesis
There is no established consensus as to what clinical findings correspond with AD. However, AD is famously characterized by the presence of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles [28]. Researchers once suggested the deposition of amyloid-beta plaques in different regions of the brain as the primary molecular basis for pathogenesis [29, 30], which, following inconsistencies [31], was modified to be smaller, more soluble amyloid oligomer assemblies rather than plaques [32, 33].

Now it is thought that AD begins with minute alterations of hippocampal synaptic function induced by diffusible oligomeric assemblies of Aβ [34], specifically AβO1-42 [35]. The rest of the disease process, including the formation of tau protein tangles, results from a production-clearance imbalance of these assemblies [32], progressing into neuronal degeneration [36–39] and memory loss [40, 41]. A pure impairment of memory is how AD usually exhibits itself in its earliest clinical phase [36].

Artificial plaque deposition
Scientists working on AD need to understand the pathogenic effects of Aβ better. While animal and in vitro models of Aβ exist and are most commonly used for this purpose [42], optogenetic methods of artificial plaque induction have also been introduced in recent years. Lim et al. [43] developed fluorescently labeled, optogenetically activated Aβ peptides that can oligomerize in vitro upon illumination. The authors concentrated on the question of how intracellular Aβ oligomers underlie the pathologies of AD and were able to put a distinction between the metabolic and physical damage of Aβ, and between the damage caused by light-induced Aβ oligomerization from mere Aβ expression. The physical damage caused by Aβ oligomers signifies tissue loss, a hallmark of late AD. Kaur et al. [44] went further and enhanced a similar method to generate in vivo Aβ aggregation.

Dissecting hippocampal memory pathways
Memory impairment in the early stages of AD is limited chiefly to episodic memory, in which the hippocampus plays a crucial part [36] (Fig. 1). AD and similar memory disorders associated with this part of the brain have sparked interest in the hippocampus’s role in memory, and neurodegenerative memory loss research has extensively focused on pathology in the medial temporal lobe, primarily in the hippocampus [45]. The neural circuits in the dentate gyrus (DG) and the CA1 regions in the
hippocampus, the first to receive signals from the cortex and the last to process them, respectively [46], were the earlier interests of scientists in the field.

It was established that optogenetic inhibition of pyramidal cells (PCs) in dorsal CA1 [47] or disinhibition through somatostatin-positive (SST) cells [48] reversibly disrupts memory acquisition. Inhibition of CA1 during recall also disrupts recall [47]. These findings underscored the importance of CA1 and suggested that a precise CA1 function is needed for both memory acquisition and recall.

Light-induced inhibition of dorsal DG, on the other hand, was found to impair only memory acquisition but not recall, whereas its hyperactivation [49] or disinhibition through hilar GABAergic neurons [50] impairs recall but not acquisition. However, this inhibition causes remarkable cognitive impairment when the mouse model needs to encode a new, conflicting memory rapidly. Consistent with former knowledge, these data revealed that CA1 is the terminal region from which the hippocampus emits output signals and is crucial for memory recall. In contrast, DG could be bypassed through alternative circuits, namely the intrahippocampal associative network of CA3 and the entorhinal cortex (EC) [51, 52].

The vast diversity of GABAergic interneurons (INs) in the hippocampus arms its microcircuits with the required flexibility for memory encoding and retrieval. Using optogenetics, it was found that a population of hippocampal GABAergic INs, known as oriens lacunosum-moleculare (OLM) cells, gatekeep the information flow in CA1, enabling the intrahippocampal transmission of information from the CA3 while reducing the influence of extrahippocampal inputs from the EC. These cells are interconnected and receive cholinergic inputs from different regions of the brain, suggesting that acetylcholine, acting through OLM cells, can control the mnemonic processes executed by the hippocampus [53].

Curious laterality in memory function is also observed in the hippocampus. Optogenetically silencing CA3 PCs on the left but not the right hippocampus impairs associative spatial long-term memory [54]. Aβ also selectively disrupts synaptic activity and facilitates long-term depression (LTD, see next section) in the left hippocampus [55], providing insights for further studies to understand the development of unusual brain lateralization in AD.

Hippocampal rhythmic oscillations
Rhythmic activity in the hippocampus occurs within distinct frequency bands, namely theta (4–12 Hz) and gamma (30–120 Hz) oscillations. Slow (30–60 Hz) and fast (60–120 Hz) gamma oscillations have also been proposed recently to have functionally distinct roles in memory [56]. These oscillations are prominent in spatial memory processing [57] and synaptic plasticity [58, 59]. Two critical models of synaptic memory learning, long-term potentiation and depression (LTP and LTD), are also closely related to the hippocampal oscillations and are involved in learning and memory formation [60, 61]. Background abnormal accumulation of amyloid oligomers is believed to be the mechanism that causes dysfunction in hippocampal parvalbumin-positive (PV) and SST IN circuits [62], which are critically involved in the induction of these oscillations, and impairs LTP by extension [34, 63–65].
Indeed, exploiting optogenetics, it was found that AβO₁₋₄₂ causes specific dysfunction in CA1 PC-to-PV IN and PV-to-PC synapses. Having no effect on PC-to-SST or SST-to-PC synapses, AβO selectively disrupts SST IN-mediated disinhibition to CA1 PC and impairs theta-nested gamma oscillation-induced spike-timing-dependent LTP [66]. AβO also increases the probability of the initial GABA release that depresses SST/PV IN's inhibitory input to CA1 PC selectively at theta and gamma frequencies, respectively [62]. These oscillations are reversible through optogenetic activation of neurons [66]. Light activation of SST and PV INs similarly restores AβO-induced theta and gamma oscillation peak power reduction, resynchronizing spike phases relative to the respective oscillations, and resynchronizes CA1 PC spikes [62].

Since theta frequency rhythmic oscillatory activity underlies a mechanism that can synchronize neural network activity during mnemonic processes [67], researchers commonly use theta-burst stimulation in order to induce LTP, especially in the hippocampus [68]. For instance, Yang et al. showed that selective optogenetic induction at theta-burst frequency in the pathway between EC layer II PCs and CA1 PV GABAergic neurons, a pathway that exhibits degeneration in AD, before the onset of symptoms, rescues degeneration of synapses and improves learning and memory function [69].

The CA1 is a point of convergence that receives gamma frequency inputs from upstream regions (CA3 and medial EC) and generates itself a faster [70] gamma oscillation. Butler et al. produced an optogenetic model of intrinsic CA1 gamma oscillations and showed that sinusoidal optical stimulation of CA1 at theta induces strong theta-nested gamma oscillations similar to in vivo, suggesting there exists a single gamma rhythm generator [71]. Using optogenetically induced theta–gamma oscillations, the authors later found that CA3 stimulation induces slower gamma oscillations in CA1 than stimulation of either medial EC or CA1 itself, where gamma oscillations are of similar frequency [72]. Optogenetic inhibition of PCs in CA1 also was not found to affect the power of the oscillations [70]. Altogether, these results reveal an excitatory-inhibitory feedback loop that underlies gamma oscillation generation in all three regions.

Increasing data is suggesting that brain network alterations rather than protein deposition could account for the early pathogenesis of AD and might even precede the canonical Aβ deposition [73], most notably the theta-gamma cross-frequency coupling [74]. Mondragón-Rodriguez et al. studied young mouse models of AD and found that not the PC inhibition by local INs nor the PV excitation by PCs, but the intrinsic excitability of PV cells was reduced in this condition. This impairment of cross-frequency coupling was not rescued by optogenetic activation of PV INs, which directly drive theta oscillations in the hippocampus, suggesting this damage does not directly result from an alteration of the underlying theta rhythm [75].

These hippocampal PV INs in the hippocampus are directly regulated by extrahippocampal networks as well, for example, medial septal PV cells (MSPVs) [76], which constitute a septohippocampal feedforward inhibitory control [77]. Optogenetic stimulation of MSPV projections in the hippocampus is associated with direct, frequency-specific pacing of hippocampal oscillations [78, 79]. In an important study, Etter et al. demonstrated how optogenetic gamma stimulation could activate MSPVs, thereby restoring hippocampal slow gamma oscillations amplitude and phase-amplitude coupling, and finally retrieving lost spatial memory despite significant plaque deposition [80].

Corticohippocampal relations

Mounting evidence suggests that the prefrontal cortex (PFC) is preferentially vulnerable to AD-related pathology [81], possibly due to metabolic demands of this region [82]. For instance, the medial PFC is among the first brain regions to develop Aβ plaques [83]. This renders the PFC an important region to study for AD researchers.

It is known that a joint contribution of the medial PFC and hippocampus supports successful spatial working memory in rodents [84, 85]. Spellman et al. established that optogenetic disruption of the gamma synchrony between these regions impaired encoding, but not maintenance or retrieval, of spatial cues [86]. Optogenetic inhibition of excitatory medial PFC neurons similarly inhibited the activation of the entorhinal-hippocampal circuit and, therefore, impaired long-term associative memory formation [87]. Altogether these data reveal that encoding of long-term episodic memory is related to an early remodeling of circuits within the neocortex and that the PFC is a crucial regulator of hippocampal activation during encoding and long-term memory formation.

Cassel et al. reported that optogenetic stimulation of the reuniens-rhomboïd nuclei (ReRh) of the thalamus induces LTP in CA1 and alters functions that are also sensitive to lesions of the hippocampus and the medial PFC [88]. On the other hand, Ito et al. reported that optogenetic silencing of Re reduced spatial memory-dependent CA1 activity, further establishing that projections from medial PFC via the Re to the hippocampus are crucial for spatial memory [89]. Maisonn et al. similarly demonstrated that light-induced Re inhibition selectively disrupts memory encoding [90]. These studies suggest that thalamic nuclei contribute to the encoding of spatial
information during working memory and may act as a gateway, relaying cortical input to the hippocampus.

The DG is the primary gate of the hippocampus and controls information flow from the cortex [91, 92], and granule cells (GCs) are the primary neurons in the DG which receive inhibition from both PV and SST GABAergic inhibitory INs. Lee et al. utilized cell-specific optogenetic perturbation and found that PV and not SST INs suppress GC responses among these cells. PV INs also control the onset, whereas SST INs regulate the later spikes [93].

The EC is another hotspot that regulates hippocampal activity. Mild cognitive impairment, which often precedes AD, is characterized by a significant neuronal loss in the EC, most notably in the layer II PCs [94, 95]. Bott et al. reported that a partial EC lesion generates hyperactivity in the DG, which could be abolished by optogenetic stimulation of hippocampal cholinergic fibers. These cholinergic fibers sprout in response to the lesion; therefore, control of DG hyperactivity by cholinergic sprouting seems to be involved in functional compensation of reduced EC glutamatergic input after a lesion of the EC [96].

**Slow waves and sleep**

Slow oscillations are crucial for memory consolidation during sleep, the power of which is commonly diminished in AD. AD-associated sleep–wake cycle disruptions include disruptions in NREM slow-wave sleep. AD patients spend less time in NREM sleep and exhibit decreased slow-wave activity. Consistent with the critical role of SWS in memory consolidation reduced SWA is associated with impaired memory consolidation [97].

Kastanenka et al. reported that inhibitory activity within the cortical circuit is responsible for slow oscillation dysfunction since light activation of excitatory cortical neurons restored slow oscillations by synchronizing neuronal activity. While optogenetic driving of slow oscillation activity halted plaque deposition and prevented calcium overload associated with this pathology [98], the authors later found that attempting to propel this circuit at an increased rate yields opposite results [99], possibly due to activity-dependent acceleration of amyloid production. This phenomenon has also been demonstrated before, through optogenetic activation of the hippocampus [100] and is consistent with former knowledge that neuronal activation increases Aβ release from presynaptic terminals [101]. There is a positive feedback loop between amyloid/tau pathology and slow-wave activity (SWA) disruptions in AD that cause even further accumulations of amyloid and tau, possibly hinting at the utility of SWA disruptions for early AD diagnosis [97].

**The forebrain**

The basal forebrain (BF) is another major controller of cortical and hippocampal activity, and its dysfunction coupled with a significant loss of its cholinergic neurons is observed in AD. Many of the BF neurons involved in said processes are, in fact, GABAergic, including a subpopulation of PV projection neurons [102]. Optogenetic stimulation of the cholinergic neurons activates the cortically projecting BF PV GABAergic neurons (CPBPGs), suggesting that the loss of cholinergic neurons in AD may partially impair cortical activation through CPBPGs [103].

CPBPGs seem to regulate gamma-band oscillations (GBO, 30–80 Hz, typically ~ 40 Hz) in the cortex. These oscillations are involved in higher cognitive functions such as attention and working memory, and their impairments are a feature of many disorders associated with dysfunction of cortical fast-spiking PV INs, including AD [104]. Indeed, Kim et al. showed that optogenetic activation or inhibition of CPBPGs can preferentially increase cortical GBO or reduce the ability of the cortex to generate GBO, respectively, indicating that this presumptively inhibitory input likely synchronizes cortical PV INs [105]. Optogenetic activation of BF PV neurons, however, unlike what is observed in hippocampal PV neurons, increases amyloid burden, suggesting that the beneficial effects of GBO on AD pathology depend on the method it is induced. In other words, activating BF inhibitory neurons preferentially suppresses cortical PV neurons rather than activating them [106]. Optogenetic stimulation of BF nuclei has also been used to establish BF modulation of sensory responses in the cortex [107].

Developing an optogenetic method for GBO induction, gamma entrainment using sensory stimuli (GENUS), laccarino, Singer et al. found that driving fast-spiking PV INs at gamma reduces levels of Aβ isoforms; hinting to a possible role of gamma rhythms in recruiting neuronal and glial responses to ameliorate AD pathology [108]. The main advantage of this study, was that this multi-sensory stimulation recruits multiple brain regions with a subsequent wider effect on the brain. It was later found that auditory GENUS boosts hippocampal function and affects microglia, astrocytes, and vasculature in the auditory cortex and hippocampus. Both auditory and visual GENUS can induce microglia clustering around plaques, which could explain how GBO induction reduces amyloid and tau burden throughout the neocortex [109].

**The cholinergic system**

Brain cholinergic neurons are critical for memory function, and their loss contributes to memory impairment in AD. One role of these neurons is to elicit theta rhythm
in the hippocampus during periods of learning when hippocampal synapses are in a state of heightened plasticity [58].

It has been established that optogenetic septal cholinergic input induces different types of hippocampal plasticity depending on the timing, all of which are disrupted by Aβ exposure [110], impairs spatial memory formation when activated at goal location but not during navigation, reduces sharp-wave ripple incidence at goal location, and enhances theta-gamma oscillations during sleep [111]. These results highlight the importance of proper timing of cholinergic input in long-term memory formation, which could explain the relatively limited success of cholinesterase inhibitors in treating AD.

Betterson et al. found that acetylcholine release in CA3 enhances light-induced gamma oscillation power in lower and decreases it in higher concentrations, acting primarily through muscarinic receptors [112]. Aitta-aho et al. similarly found that while brainstem acetylcholine neurons transiently excite amygdala neurons through glutamate, BF acetylcholine neurons cause biphasic inhibition-excitation responses that synchronize amygdala activity. The authors suggested that the brainstem and the BF inputs to the amygdala might drive opposing learning behaviors [113].

Forebrain cholinergic neurons also regulate innate immune responses and inflammation, which is interesting to note, considering that anti-inflammatory regulation is often impaired in diseases associated with cholinergic dysfunction, including AD. In one study, selective optogenetic stimulation of BF cholinergic neurons was found to significantly reduce serum TNF levels, a marker of inflammation [114].

Memory engrams

Hippocampal cells, thought to represent “memory engrams,” have been optogenetically targeted to better understand the circuits involved in AD-related memory pathology. In a critical study, Roy, Arons et al. showed that in early AD amnesia, direct optogenetic activation of memory engram cells could retrieve lost memory, suggesting a retrieval rather than a storage impairment. The authors optically induced LTP at perforant path synapses of DG engram cells and reported restoration of both spine density and long-term memory, a reduction in which is the underlying mechanism of age-dependent amnesia that precedes plaque deposition [115]. Bostanci̇klioğlu similarly showed that optogenetic manipulation of serotonin nuclei retrieve the lost memory by closing potassium channels on the memory engram cells, raising questions about the effects of serotonin on memory engram cells and pointing to the possible interface between the amyloid-centric hypothesis of AD and the memory engram hypothesis in order to explain memory loss in AD [116].

In order to visualize memory traces, Denny et al. created a transgenic line of mice that allowed for the comparison between cells activated during encoding and expression of memory. Mice re-exposed to a context had more reactivated cells in the DG and CA3 than mice exposed to a novel context. Over time, these differences disappeared, in keeping with the observation that memories become generalized. Optogenetically silencing DG or CA3 cells that were recruited during encoding of a fear-inducing context prevented the expression of the corresponding memory. Mice with reduced neurogenesis displayed less contextual memory and less reactivation in the CA3, but surprisingly, regular reactivation in the DG [117]. The results suggest that distinct memory traces are located in the DG and CA3, but the strength of the memory is related to reactivation in the CA3.

Emotions and memory

Depression is commonly observed in patients with dementia [118], such as AD [119]. Animal studies have also confirmed a causal relation in that depression can impair memory [120, 121]. The basolateral amygdala (BL) is famously being associated with emotion and motivation, playing an essential role in processing emotion-associated events. BL has neuronal fibers directly projecting to the hippocampus [122] and regulates long-term potentiation of the dorsal hippocampus [123] and hippocampal plasticity [124].

Yang et al. developed mouse models of learned hopelessness and learned hopefulness (LHL and LHF), which are models of memory impairment and enhancement resulting from negative and positive emotions, respectively. The authors found that opposite scaling of the excitatory monosynaptic connection between posterior BL (BLP) and ventral CA1 governs the modified spatial learning and memory. More interestingly, optogenetic disruption of this circuit abolishes the effects of LHF and impairs synaptic plasticity, whereas its stimulation rescues the LHL-induced memory deficits [125].

“Sundowning” is another emotional disturbance in AD, characterized by early-evening agitation and aggression [126]. Exploiting optogenetic mapping technics, Todd et al. found that a population of GABAergic subparaventricular zone neurons, which are major postsynaptic targets of the central circadian clock, receive input from neurons in the aggression regulating region of the hypothalamus and revealed a functional circuit by which the circadian clock regulates aggression [127], explaining the daily rhythmicity of this phenomenon.
Neurogenesis
The hippocampus, most notably the DG, is a plastic and vulnerable structure in which neurogenesis occurs in embryonic and postnatal periods, and impairments in neurogenesis are one of the key manifestations of Aβ pathology [128]. Morgun et al. found that aberrant mechanisms of development of stem and progenitor cells caused by Aβ1-42 can be partially restored through targeted optogenetic activation of certain astrocytes in the neurogenic niche [129].

Duan et al. have recently presented an optogenetic tool to study the nerve growth factor/tropomyosin receptor kinase A signaling pathway, which plays a key role in neuronal development, function, survival, and growth, and is implicated in neurodegenerative disorders. However, this tool has yet to be used in the context of AD [130].

Drug function
Optogenetic tools have also been used to test drug function. Memantine has been shown to improve cognitive functions AD models. Using optogenetics, it was established that memantine enhanced EC to CA1 synaptic neurotransmission and promoted dendritic spine regeneration of EC neurons that projected to CA1 [131]. Caffeine consumption prevents memory deficits in aging and AD through the antagonism of adenosine receptors, optogenetic activation of which in the hippocampus impairs spatial memory performance [132].

Neurovascular dysfunction
AD is associated with neurovascular dysfunction, pericyte loss, and reduced cerebral blood flow [133]. Optogenetic manipulation of the activity of individual and small clusters of mural cells and consequent imaging techniques together with system modeling methods [134] have been used to allow the investigation of pericyte and smooth muscle cell physiology and their role in regulating cerebral blood flow [135]. One study, for instance, noted that optogenetic excitation of pericytes results in contraction followed by constriction of the underlying capillary leading to a decrease in capillary diameter and reduced capillary RBC flow [136].

Cellular stress
DNA damage is intimately connected to aging and the manifestation of age-related neurodegenerative disorders such as AD [137]. Suberbielle et al. showed that DNA double-strand breaks that naturally occur during exploration of a new environment are increased in AD and are even more severe after optogenetic stimulation. The authors found that suppressing aberrant neuronal activity, and improving learning and memory, normalized DSB levels [138].

Aβ1-42 induces oxidative stress in AD [139]. Using zebrafish as a model, Formella et al. utilized a genetically encoded photosensitizer that produces reactive oxygen species upon stimulation to study oxidative stress and neurodegeneration. It was found that neural cells undergo stress and cell death similar to what is seen in several neurodegenerative diseases, including AD [140].

Role of optogenetics in Alzheimer’s disease treatment
Conventional AD treatments
AD treatment remains symptomatic without changing the disease prognosis, and there is no definitive cure available for it, which could slow the disease progression and mitigate cognitive and memory impairments [141, 142]. To date, only seven medical treatments have been approved for AD by the United States Food and Drug Administration (FDA): Six treatments (including Donepezil, Galantamine, Rivastigmine, Memantine, Memantine+Donepezil, Suvorexant) act to control symptoms rather than changing the course of the disease, and one treatment (Aducanumab) may delay the clinical decline [143]. Most clinical therapeutic approaches use passive immunotherapies with monoclonal antibodies to clear Aβ peptides and tau proteins [144].

The recent approval of Aducanumab reignited the interest around novel therapeutic approaches, as it marks the first approved disease-modifying therapy for AD [145, 146]. Lamentably, Aducanumab is one of the very few clinical trials that have investigated AD treatments in the last two decades. The general outcome for these trials is considered a big failure, with an overall success rate of 0.4% during the 2002–2012 period [147]. This rate emphasizes the need to identify different therapeutic plans for AD treatment.

Optogenetics and AD treatment in animal studies
Optogenetics could, in theory, be an alternative therapeutic strategy against AD. However, as the field stands today, there are major translational obstacles to overcome (see section ‘Clinical application challenges’) if optogenetic methods are to be embedded into the clinic. These tactics can embark on better therapeutic interventions, alongside their other advantages, for pathophysiological studies and screening purposes [2]. The use of optogenetics, even if not directly therapeutic, can also provide insight into the mechanism of action and development of other forms of treatment [148] (Fig. 2). The chief advantage of using optogenetics over conventional electrical or pharmacological techniques may be more precise targeting of specific neural elements, greater cellular and temporospatial specificity, and reduced off-target effects [149–151].
Different murine studies on AD model mice have shown promising results. For example, Yang et al. found an effective way for rescuing synaptic decay and developing spatial learning and memory by optogenetic activation of EC layer II-CA1 PV synapses with theta-burst stimulation (see section ‘hippocampal rhythmic oscillations’) [69]. Roy et al. suggested that the dendritic spine density loss in DG neurons can be reversed in early AD stages using optogenetic techniques. They also reported that stimulating photo-activating DG engram cells could lead to episodic memory recall [115] (see section ‘Memory engrams’). Perusini et al. separately studied optogenetic stimulation of DG and reported reactivation of previously learned neural memory ensembles and memory improvement in AD model mice [152].

Gamma oscillations (see section ‘Hippocampal rhythmic oscillations’) are essential for higher cognitive functions and sensory responses [153–155], and changes in them (20–50 Hz) have been observed in various neurological conditions, including AD [156, 157]. Iaccarino, Singer et al. used optogenetics to spike these oscillations at 40 Hz in the hippocampus of 5XFAD mice and reported a dramatic reduction of Aβ peptides followed by microglia response [108] (see section ‘The forebrain’).

Robinson et al. investigated the effect of optogenetic techniques on neurotransmitter signals and ascertained that optogenetically activating glutamatergic neurons could facilitate learning and memory by theta-wave generation in the hippocampus [158]. Optogenetic activation of glutamatergic neurons in the bilateral DG in AD has been shown to improve working and short-term but not long-term memory, associated with increased expression of glutamate receptors in the hippocampus [159, 160]. It was also established that glutamate receptor upregulation varies in various hippocampus regions, suggesting that a single-target optogenetics strategy has spatial limitations and a multiple targeted optogenetics approach to AD therapy should be explored [160].

GABA levels are different in wild and AD model mice brains. GABA downregulates Aβ uptake in neurons; therefore, relatively high levels of GABA decrease Aβ-induced cytotoxicity. GABA treatment also decreases basal levels of cell death. Application of GABA during early life at an early age but not at older ages can improve cognitive function significantly. Activating or suppressing GABA(A) receptors by optogenetic methods also confirmed that GABA activation at young age ameliorated Aβ pathology, suggesting early life GABA as AD treatment [161]. In another research, Zhang et al. found that optogenetic stimulation of GABAergic neurons in the hippocampus of APP/PS1 mice induced autophagy, mitigated neuroinflammation, reduced Aβ fragments, and completely reversed the learning impairment [162].

Mancuso et al. suggested that despite the anatomical depth of their cell bodies, cholinergic projection neurons provide a better target for systems-level optogenetic modulation in AD treatment than cholinergic INs found in several brain regions, including the cortex and
the striatum that are activated in traditional deep brain stimulation [163].

Feasible brain sites for optogenetic-mediated therapy
Although the whole brain structure acts as a unit and the activity of the whole system should be considered for interventional studies on AD and memory loss, it is not always practical to modify the entire brain to access the effect of optogenetic stimulation [45], especially given that most vectors modify the genome in order to reach stable levels of opsin expression. Some studies have identified hippocampal formation as the most prominent site for interventions to enhance memory [164–166], together with sites that work in conjunction with the hippocampus, such as frontal and retrosplenial cortices [167–170]. Other studies suggested targeting major input/output regions such as the EC and area CA1 [69, 171–173].

Today, the main focus is on small brain structures which innervate and regulate hippocampal and cortical regions. One of these structures is the small thalamic nuclei [174–176], particularly anterior thalamic nuclei (ATN). ATN has a strategic position and extensive cortical connections [177–179], and its anteroventral nucleus (AV) comprises a large population of theta frequency cells that coordinate memory [180]. Another small structure is the mammillary body (MB) which neurons are connected to ATN and fire at theta frequency, but its location on the ventral surface of the brain makes it a difficult target for optogenetics [181]. The nucleus Re is the third site of interest because of its dense reciprocal connections with the PFC and the hippocampus, directly innervating the CA1 area [175]. The Re connections suggest it has a vital role in mnemonic functions [182, 183]. One specific study reported working memory impairment due to delta frequency optogenetic stimulation of transduced Re terminals [184].

Clinical application challenges
The main hurdle is taking research results from the laboratory into the clinic, specifically the delivery of optogenetic tools in patients. As Shen et al. stated, the minimum requirements of an ideal clinical optogenetic therapy would be: (1) a safe and efficient gene delivery vehicle; (2) targeting of the gene delivery vehicle to the tissue of interest; (3) a delivery vehicle, transgene, and therapeutic protein gene-product, that is non-immunogenic and non-mutagenic; and (4) an optogenetic protein that is highly sensitive to light in the red to near-infrared wavelength range (to keep light doses low, maximize light penetration, and minimize photodamage) [185].

Gene delivery vehicle
Presently, viral vector-based transduction is the most forward-looking, persuasive, and commonly used method to deliver foreign genes to specific tissues in mammals [186]. Different phases of clinical trials also proved the safety of using the adeno-associated virus (AAV) as a viral agent in humans [187].

Targeting the gene to a specific tissue
Local virus injections are used to deliver optogenetic tools to the central and peripheral nervous systems in rodents. This prevents the virus from direct contact with the bloodstream and its circulating antibodies. However, local stereotaxic injection into the human brain is not as easy as rodents and will require imaging and expert analysis. Engineered AAV capsids such as the AAVDJ are found to have increased spreading capacity with promising perspectives [188].

Other alternatives to this approach include delivering AAV to the cerebrospinal fluid, which transfers the gene throughout the brain and spinal cord [189]. Nevertheless, the tight junctions of ependymal cells will restrict AAV entry into the brain parenchyma and makes its use less practical, unlike rodents [190].

Light delivery
Delivering light to the brain is also more complicated in primates and humans than rodents because of the larger size of their brains, and the deeper positioning as some of the important target structures such as the hippocampus and the thalamus (see section ‘Feasible brain sites for optogenetic-mediated therapy’). Strategies such as using an epidural optic fiber or small-scale bio-optoelectronic implants to deliver light are considered invasive procedures and may be helpful in mice. However, it is far from being used in humans and may be accompanied by side effects, such as tissue overheating and damage by light, tissue scarring, or infection [191, 192]. This makes light delivery possibly the largest obstacle on the path of therapeutic optogenetics.

Immunogenicity and genotoxicity
All gene- and protein-based therapies, including optogenetic-based therapies, bring the possibility of adverse immune responses. So, the potential risk of opsin, a foreign protein antigen, as an autoimmune agent in patients must be considered if safe optogenetic therapeutics are to be developed in the future [193]. Moreover, it must be taken into account that there may be pre-existing immunity against the AAV delivery vehicle itself. Even at low levels, anti-AAV antibodies
Recent therapeutic developments

Despite all the challenges, optogenetics has been safely and effectively applied to awake non-human primate rhesus macaques (Macaca mulatta) [196, 197], which is remarkable, as primate studies take the field closer to the clinic. Another impressive effort was the first reported case of partial functional recovery in a neurodegenerative disease after optogenetic therapy, reported in July 2021. In this effort, the partial vision was recovered in one participant, a 58-year-old male diagnosed with retinitis pigmentosa [198]. This, despite the challenges listed above, shows a promising prospective for considering optogenetics as an alternative in the future therapeutic methods of neurodegenerative conditions, including AD.

Abbreviations

AD: Alzheimer’s disease; IN: Interneuron; LFP: Local field potentials; LTP: Long term potentiation; SST: Somatotropin-positive; PV: Parvalbumin-positive; PC: Pyramidal cell; EC: Entorhinal cortex; PFC: Prefrontal cortex; DG: Dentate gyrus; BF: Basal forebrain; Aβ: Amyloid beta; AβO1–42: Amyloid beta (1–42) oligomers; GC: Granule cells.

Authors’ contributions

PM, AK: drafting of the manuscript/study conception and design/data acquisition/data interpretation, GP: critical revision and data interpretation, PS, PM, AK: drafting of the manuscript/study conception and design/data acquisition/data interpretation, NR: study conception and design/critical revision. All authors have read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 School of Medicine, Tehran University of Medical Sciences (TUMS), Children’s Medical Center Hospital, Dr. Qarib St., Keshavarz Blvd, 14194 Tehran, Iran.
2 Network of Immunity in Infection, Malignancy and Autoimmunity (NIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
3 Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
4 Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
5 Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
6 Department of Biology and Neurosciences Institute, University of Texas at San Antonio (UTSA), San Antonio, TX, USA.
7 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
8 Research Center for Immunodeficiencies, Children’s Medical Center, Dr. Gharib St, Keshavarz Blvd, Tehran, Iran.

References

1. Dumurgier J, Sabia S. Epidemiology of Alzheimer’s disease: latest trends. Rev Prat. 2020;70(2):149–51.
2. Suresh J, Khor IW, Kaur P, Heng HL, Torta F, Dawe GS, et al. Shared signaling pathways in Alzheimer’s and metabolic disease may point to new treatment approaches. FEBS J. 2021;288(12):3855–73.
3. Crick FH. Thinking about the brain. Sci Am. 1979;241(3):219–32.
4. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci. 2005;8(9):1263–8.
5. Li X, Gutierrez DV, Hanson MG, Han J, Mark MD, Chiel H, et al. Fast noninvasive activation and inhibition of neural and network activity by vertebrate rhodopsin and green algae channelrhodopsin. Proc Natl Acad Sci USA. 2005;102(49):17816–21.
6. Shemesh OA, Tanese D, Zampini V, Linghu C, Piatkevich K, Ronzitti E, et al. Temporally precise single-cell-resolution optogenetics. Nat Neurosci. 2017;20(12):1796–806.
7. Packer AM, Roska B, Hauser M. Targeting neurons and photons for optogenetics. Nat Neurosci. 2013;16(7):805–15.
8. McNally JM, Aguilar DD, Katsuki F, Radzik LK, Uygun DS, McNenna JT, Steecker RE, Deisseroth K, Spudich JL. Optogenetic manipulation of an ascending arousal system tunes cortical broadband gamma power and reveals functional deficits relevant to schizophrenia. Mol Psychiatry. 2021;26(7):3461–75.
9. Kim CK, Adhikani A, Deisseroth K. Integration of optogenetics with complementary methodologies in systems neuroscience. Nat Rev Neurosci. 2017;18(4):225–35.
10. Heston J, Friedman A, Baqui M, Bavafa N, Aron AR, Hnasko TS. Activation of subthalamic nucleus stop circuit disrupts cognitive performance. eNeuro. 2020;7(5):12.
11. Hamott AM, Chung DY, Uner A, Bozdaky RO, Moraes A, Takizawa T, Qin T, Ayata C. Optogenetic Spreading Depression Elicits Trigeminal Pain and Anxiety Behavior. Ann Neurol. 2021;89(1):119–90.
12. Bernstein JG, Boyden ES. Optogenetic tools for analyzing the neural circuits of behavior. Trends Cogn Sci. 2011;15(12):592–600.
13. Zhang F, Gradinaru V, Adamantidis AR, Durand R, Arian RD, de Leece L, et al. Optogenetic interrogation of neural circuits: technology for probing mammalian brain structures. Nat Protoc. 2010;5(3):439–56.
14. Obi-Nagata K, Temma Y, Hayashi-Takagi A. Synaptic functions and their disruption in schizophrenia: from clinical evidence to synaptic optogenetics in an animal model. Proc Jpn Acad Ser B. 2019;95(5):179–97.
15. Oesterhelt D, Steocenius W. Rhodopsin-like protein from the purple membrane of Halobacterium halobium. Nat New Biol. 1971;233(39):149–52.
16. Kato HE, Zhang F, Yizhar O, Ramakrishnan C, Nishizawa T, Hiraoka K, et al. Crystal structure of the channelrhodopsin light-gated cation channel. Nature. 2012;482(7385):369–74.
17. Cho YK, Li D. Optogenetics: basic concepts and their development. In: Kianianmomeni A, editor. Optogenetics: methods and protocols. New York: Springer; 2016. p. 1–17.
18. Guru A, Post RJ, Ho YY, Warden MR. Making sense of optogenetics. Int J Neuropsychopharmacol. 2015. https://doi.org/10.1093/ijnppy/pvy079.
19. Govorunova EG, Sineshchekov OA, Li H, Spudich JL. Microbial rhodopsins: diversity, mechanisms, and optogenetic applications. Annu Rev Biochem. 2017;86:845–72.
20. Fenno L, Yizhar O, Deisseroth K. The development and application of optogenetics. Annu Rev Neurosci. 2011;34(1):389–412.
21. Aron RD, Thompson KR, Fan LL, Bernstein H, Deisseroth K. Temporally precise in vivo control of intracellular signalling. Nature. 2009;458(7241):1025–9.
22. Ramamoorth M, Narvekar A. Non viral vectors in gene therapy—an overview. J Clin Diagn Res. 2015;9(11):GD1–6.
23. Kim TJ, McColl JC, Jung YH, Huang X, Suada ER, Li Y, et al. Injectable, cellular-scale optoelectronics with applications for wireless optogenetics. Science. 2013;340(6129):211–6.
24. Huber D, Petreanu L, Ghtani N, Ranade S, Hromadka T, Mainen Z, et al. Sparse optical microstimulation in barrel cortex drives learned behaviour in freely moving mice. Nature. 2008;451(7174):61–4.

25. Ruiz O, Lustig BR, Nasji JI, Cetin A, Reynolds JH, Albright TD, et al. Optogenetics through windows on the brain in the nonhuman primate. J Neurophysiol. 2013;110(6):1455–67.

26. Wang Y, Gong Q, Li Y, Li AZ, Zhang YG, Cao CF, et al. A wireless remote high-power laser device for optogenetic experiments. Laser Phys. 2015;25(4):045601.

27. Appasani K, Appasani RK. Introduction to optogenetics: from neuronal function to mapping and disease biology. In: Appasani K, editor. Optogenetics: from neuronal function to mapping and disease biology. Cambridge: Cambridge University Press; 2017. p. 3–17.

28. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–66.

29. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat Rev Neurosci. 2007;8(7):499–509.

30. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12(10):383–8.

31. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol. 1988;23(2):138–44.

32. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):333.

33. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer’s-related amyloid β oligomers. J Neurosci. 2004;24(45):10191.

34. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95(11):6448.

35. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry. 1993;32(18):4693–7.

36. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2003;307(5710):745–52.

37. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurotoxicity from soluble pool of Aβ amyloid as a determinant of severity of neurodegenerative disorders. Trends Pharmacol Sci. 2002;23(4):145–57.

38. Shankar GM, Mikelovíc S, Leão KE, Gezelius H, Enjin A, et al. OLM interneurons differentially modulate CA3 and entorhinal inputs to hippocampal CA1 neurons. Nat Neurosci. 2012;15(11):1524–30.

39. Shipton OA, El-Gaby M, Apergis-Schoute J, Deisseroth K, Bannerman DM, Paulsen O, et al. Left–right dissociation of hippocampal memory processes in mice. Proc Natl Acad Sci USA. 2014;111(42):15238.

40. O’Riordan KJ, Hu N-W, Rowan MJ. Aβ facilitates LTD at Schaffer collateral synapses preferentially in the left hippocampus. Cell Rep. 2018;22(8):2053–65.

41. Zheng C, Bieri KW, Hsiao YT, Colgin LL. Spatial sequence coding differs during slow and fast gamma rhythms in the hippocampus. Neuron. 2016;89(2):398–408.

42. Drago G, Buzsáki G. Temporal encoding of place sequences by hippocampal cell assemblies. Neuron. 2006;50(1):145–57.

43. Huerta PT, Lisman JE. Heightened synaptic plasticity of hippocampal CA1 neurons during a cholinergically induced rhythmic state. Nature. 1993;364(6439):723–5.

44. Bikbaev A, Manahan-Vaughan D. Relationship of hippocampal theta and gamma oscillations to potentiation of synaptic transmission. Front Neurosci. 2008. https://doi.org/10.3389/neuro.01.010.2008.

45. Lamto T. The discovery of long-term potentiation. Philos Trans R Soc Lond B. 2003;358(1432):617–20.

46. Kemp A, Manahan-Vaughan D. Hippocampal long-term depression: master or minion in declarative memory processes? Trends Neurosci. 2007;30(3):111–8.

47. Chung H, Park K, Jang HJ, Kohl MM, Kwag J. Dissociation of somatostatin and parvalbumin interneurons circuit dysfunctions underlying hippocampal theta and gamma oscillations impaired by amyloid β oligomers in vivo. Brain Struct Funct. 2020;225(3):935–54.

48. Wang H-W, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, et al. Soluble oligomers of β amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002;94(2):133–40.

49. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837–42.

50. Park K, Lee J, Jang HJ, Richards BA, Kohl MM, Kwag J. Optogenetic activation of parvalbumin and somatostatin interneurons selectively restores theta-nested gamma oscillations and oscillation-induced spike timing-dependent long-term potentiation impaired by amyloid β oligomers. BMC Biol. 2020;18(1):7.

51. Colgin LL. Mechanisms and functions of theta rhythms. Annu Rev Neurosci. 2013;36(1):295–312.

52. Bowden JB, Abraham WC, Harris KM. Differential effects of strain, circadian cycle, and stimulation pattern on LTP and concurrent LTD in the dentate gyrus of freely moving rats. Hippocampus. 2012;22(6):1363–70.

53. Yang X, Yao C, Tan T, Li X, Yan H, Wu J, et al. A novel mechanism of memory loss in Alzheimer’s disease mice via the degeneration of entorhinal-CA1 synapses. Mol Psychiatry. 2018;23(2):199–210.
70. Craig MT, McBain CJ. Fast gamma oscillations are generated intrinsically in CA1 without the involvement of fast-spiking basket cells. J Neurosci. 2015;35(8):3616.

71. Butler JL, Mendonca PRF, Robinson HPC, Paulsen O. Intrinsically coherent area 1 theta-nested gamma oscillations induced by optogenetic theta frequency stimulation. J Neurosci. 2016;36(15):4155–69.

72. Butler JL, Hay YA, Paulsen O. Comparison of three gamma oscillations in the mouse entorhinal–hippocampal system. Eur J Neurosci. 2018;48(8):2795–806.

73. Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci. 2016;17(12):777–92.

74. Goutagny R, Gu N, Cavanagh C, Jackson J, Quirion R, et al. Alterations in hippocampal network oscillations and theta–gamma coupling arise before AB overproduction in a mouse model of Alzheimer’s disease. Eur J Neurosci. 2013;37(12):1896–902.

75. Mondragon-Rodriguez S, Gu N, Marien F, Williams S. Alzheimer’s transgenic model is characterized by very early brain network alterations and beta-CTF fragment accumulation: reversal by beta-sestinate inhibition. Front Cell Neurosci. 2018;12:17.

76. Amihon B, Huh CY, Manseau F, Ducharme G, Nichol H, Adamantidis A, et al. Parvalbumin interneurons of hippocampus tune population activity at theta frequency. Neurosci. 2015;36(15):1277–89.

77. Unal G, Joshi R, Schaffer HE, Lavenex P. Somogyi P. Synaptic targets of medial septal projections in the hippocampus and extrahippocampal cortices of the mouse. J Neurosci. 2015;35(48):15812.

78. Bender F, Gorbati M, Cadaviec MC, Denisova N, Gao X, Holman C, et al. Theta oscillations regulate the speed of locomotion via a hippocampus to lateral septum pathway. Nat Commun. 2015;6(1):6521.

79. Zutshi I, Brandon MP, Fu ML, Donegan ML, Leutgeb JK, Leutgeb S. Hippocampal neural circuits respond to optogenetic pacing of theta frequencies by generating accelerated oscillation frequencies. Curr Biol. 2018;28(8):1179-88.e3.

80. Etter G, van der Veldt S, Manseau F, Zarrinkoub I, Trillaud-Doppia E, Williams S. Optogenetic gamma stimulation rescues memory impairments in an Alzheimer’s disease mouse model. Nat Commun. 2019;10(1):5322.

81. Jones DT, Machulda MM, Vemuri P, McDade EM, Zeng G, Senjem ML, et al. Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology. 2011;77(16):1524.

82. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709–17.

83. Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011;3(77):77rs1.

84. Martorell AJ, Paulson AL, Suk H-J, Abdurrob F, Drummond GT, Guan W, et al. Multi-sensory gamma stimulation ameliorates Alzheimer’s-associative pathology and improves cognition. Cell. 2019;177(2):256-71.e22.

85. Yang C, McKenna JT, Zant JC, Winston S, Abarr KK, Rigby MS, et al. Distribution and intrinsic membrane properties of basal forebrain GABAergic and parvalbumin neurons in the mouse. J Comp Neurol. 2013;521(16):1225–50.

86. Yang C, McKenna JT, Zant JC, Winston S, Basheer R, Brown RE. Cholinergic neurons excite cortically projecting basal forebrain GABAergic neurons. J Neurosci. 2014;34(8):2832–44.

87. Kim T, Thackabhan S, McKenna JT, McNally JH, Yang C, Choi JH, et al. Cortically projecting basal forebrain parvalbumin neurons regulate cortical gamma band oscillations. Proc Natl Acad Sci USA. 2015;112(11):3535.

88. Wilson CA, Fouda S, Sakata S. Effects of optogenetic stimulation of basal forebrain parvalbumin neurons on Alzheimer’s disease pathology. Sci Rep. 2020;10(1):15456.

89. Chavez-Coira I, Martinez-Cortese J, Nunez A, Rodrigo-Angulo ML. Basal forebrain nuclei display distinct projecting pathways and functional circuits to sensory primary and prefrontal cortices in the rat. Front Neuroanat. 2018;12:15.

90. laccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham T, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016;534(7608):220–5.

91. Martorell AJ, Paulson AL, Suk H-J, Abdurrob F, Drummond GT, Guan W, et al. Multi-sensory gamma stimulation ameliorates Alzheimer’s-associated pathology and improves cognition. Cell. 2019;177(2):256-71.e22.

92. Acsády L, Káli S. Models, structure, function: the transformation of cortical signals in the dentate gyrus. In: Scharfman HE, editor. Progress in brain research, vol. 163. Amsterdam: Elsevier; 2007. p. 3–790.
114. Lehner KR, Silverman HA, Adorissio ME, Roy A, Al-Onaizi MA, Levine Y, et al. Forebrain cholinergic signaling regulates innate immune responses and inflammation. Front Immunol. 2019;10:11.

115. Roy DS, Arons A, Mitchell TJ, Pignatelli M, Ryan TJ, Tonegawa S. Memory retrieval by activating engram cells in mouse models of early Alzheimer’s disease. Nature. 2016;531(7595):508–12.

116. Bostanciikoglou M. Optogenetic stimulation of serotonin nuclei retrieve the lost memory in Alzheimer’s disease. J Cell Physiol. 2020;235(2):836–47.

117. Denny Christine A, Kheirbek Mazen A, Alba Eva L, Tanaka Kenji F, Brachman Rebecca A, Laughman Kimberly B, et al. Hippocampal memory traces are differentially modulated by experience, time, and adult neurogenesis. Neuron. 2014;83(1):189–201.

118. Patrick S, Verdier-Taillefer M-H, Dufouil C, Alpérovitch A. Depressive symptoms and cognitive decline in elderly people: longitudinal study. Br J Psychiatry. 2002;181(5):406–10.

119. Starkstein SE, Jorge R, Mizrahi R, Robinson RG. The construct of memory impairment in dementia. J Neurosci. 2005;162(11):2086–93.

120. LeGates TA, Altimus CM, Wang H, Lee H-K, Yang S, Zhao H, et al. Aberrant light directly impairs mood and learning through melanopin-expressing neurons. Nature. 2012;491(7425):594–8.

121. Song L, Che W, Min-wei W, Murakami Y, Matsumoto K. Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol Biochem Behav. 2006;83(2):186–93.

122. Pikkarainen M, Rönkkö S, Savander V, Insuitti R, Pikkanen A. Projections from the lateral, basal, and accessory basal nuclei of the amygdala to the hippocampal formation in rat. J Comp Neurol. 1999;403(2):229–60.

123. Ikegaya Y, Saito H, Abe K. The basomedial and basolateral amygdaloid nuclei contribute to the induction of long-term potentiation in the dentate gyrus in vivo. Eur J Neurosci. 1996;8(9):1833–9.

124. Akirav I, Richter-Levin G. Mechanisms of amygdala modulation of hippocampal plasticity. J Neurosci. 2002;22(22):9912.

125. Yang Y, Wang ZH, Jin S, Gao D, Liu N, Chen SP, et al. Opposite monosynaptic activity and inflammation. Front Immunol. 2019;10:11.

126. Hollands C, Bartolotti N, Lazarov O. Alzheimer’s disease and hippocampal plasticity: Exploring shared mechanisms. Front Neurosci. 2016;10:178.

127. Morgan AV, Osipova ED, Boytsov EB, Shuvaev AN, Komleva YK, et al. Astrocyte-mediated regulation of cell development in the model of neurogenic niche in vitro treated with A beta1–42. Biochem Mosc Suppl Ser B. 2020;14(1):6–14.

128. Duan LT, Hope JM, Guo SL, Ong QX, Francois A, Kaplan L, et al. Optical activation of TrkA signaling. ACS Synth Biol. 2018;7(7):1685–93.

129. Li P, Xu J, Gu HH, Peng H, Yin Y, Zhuang JH. Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal-CAl projection. BMC Neurosci. 2022;21(1):8.

130. Li P, Rial D, Canas PM, Yoo JH, Li W, Zhou X, et al. Optogenetic activation of intracellular adenosine A2A receptor signaling in the hippocampus is sufficient to trigger CREB phosphorylation and impaired memory. Mol Psychiatry. 2015;20(11):1339–49.

131. Kisler K, Nelson AV, Montague A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419–34.

132. Chen RCH, Atry F, Richner T, Brodnick S, Pisanello J, Ness J, et al. System identification analysis of optogenetically evoked electrocorticography and cerebral blood flow responses. J Neural Eng. 2020;17(5):26.

133. Tong L, Hill RA, Damisch EC, Murray KN, Yuan P, Bordey A, et al. Imaging and optogenetic modulation of vascular mural cells in the live brain. Nat Protoc. 2021;16(1):472–96.

134. Nelson AV, Sagare MA, Wang YM, Kisler K, Zhao Z, Zlokovic BV. Channelrhodopsin excitation contracts brain pericytes and reduces blood flow in the aging mouse brain in vivo. Front Aging Neurosci. 2020;12:11.

135. Madabhushi R, Pan L, Tsai L-H. DNA damage and its links to neurodegeneration. Neuron. 2014;83(2):266–82.

136. Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, et al. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-beta. Nat Neurosci. 2013. https://doi.org/10.1038/nn.3556.

137. Butterfield DA, Sworm AM, Sultana R. Amyloid-β-peptide (1–42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal. 2012;19(8):823–35.

138. Formella I, Svanh AJ, Radford RAW, Don EK, Cole NJ, Hogan A, et al. Real-time visualization of oxidative stress-mediated neurodegeneration of a single spinal motor neurons in vivo. Redox Biol. 2018;19:226–34.

139. Yannopoulos KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis. 2020;12:1179573520907397.

140. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Barnerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet (London, England). 2020;396:413–46.

141. Alzheimer’s A. FDA-approved treatments for Alzheimer’s. Chicago; 2021.

142. Perusini JN, Cajigas SA, Cohensedgh O, Lim SC, Pavlova IP, Donaldson ZR, et al. Optogenetic stimulation of dentate gyrus engrams restores memory in Alzheimer’s mouse hippocampus. 2017;27(10):1110–22.

143. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science. 2009;324(5925):354–5.

144. van Duuren E, van der Plasse G, van der Blom R, Joosten RN, Mulder AB, Pennartz CM, et al. Pharmacological manipulation of neuronal ensemble activity by reverse microdialysis in freely moving rats: a comparative study of the effects of tetradoxotin, lidocaine, and muscimol. J Pharmacol Exp Ther. 2007;323(1):61–9.

145. Niell DR, Biko M, Jeffreys JS. Electrical stimulation of excitatory tissue: design of efficacious and safe protocols. J Neurosci Methods. 2005;141(2):171–98.

146. van Duuren E, van der Plasse G, van der Blom R, Joosten RN, Mulder AB, Pennartz CM, et al. Pharmacological manipulation of neuronal ensemble activity by reverse microdialysis in freely moving rats: a comparative study of the effects of tetradoxotin, lidocaine, and muscimol. J Pharmacol Exp Ther. 2007;323(1):61–9.

147. Fries P, Nikolic D, Singer W. The gamma cycle. Trends Neurosci. 2007;30(7):309–16.

148. Fries P, Nikolic D, Singer W. Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. Nature. 1989;338(6213):334–7.

149. Buzsáki G. Rhythms of the brain. New York: Oxford University Press; 2006. xx, 448-xx, p.

150. Kalenak A, Czuczwar S, Göke B, Knight AJ, Klymienko I, et al. Amantadine increases hippocampal plasticity in mouse models of Alzheimer’s disease. Neuron. 2020;12(1):1179573520907397.
161. Sun XQ, Meng XL, Zhang J, Li YH, Wang LP, Qin XY, et al. GABA attenuates amyloid toxicity by downregulating its endocytosis and improves cognitive impairment. J Alzheimers Dis. 2012;31(3):635–49.

162. Zhang Z, Jing Y, Ma Y, Duan D, Li B, Holscher C, et al. Driving GABAergic neurons optogenetically improves learning, reduces amyloid load and enhances autophagy in a mouse model of Alzheimer’s disease. Biochem Biophys Res Commun. 2020;525(4):928–35.

163. Mancuso J, Chen XY, Zhao Z, Li XP, Xue Z, Wong STC. Optogenetic stimulation of cholinergic projection neurons as an alternative for deep brain stimulation for Alzheimer’s treatment. In: Kollias N, Choi B, Zeng H, Kang H-Y, Knudson BE, Wong BJ, et al., editors. Photonic therapeutics and diagnostics IX. Proceedings of SPIE. 8565. Bellingham: Spie-Int Soc Opti Engineering. 2013.

164. Drapeau E, Mayo W, Aurotsseus C, Le Moal M, Piazza PV, Abrous DN. Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis. Proc Natl Acad Sci USA. 2003;100(24):14385–90.

165. Neves G, Cooke SF, TV. Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nat Rev Neurosci. 2008;9(1):65–75.

166. Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci. 2010;11(5):339–50.

167. Vann SD. Gudden’s ventral tegmental nucleus is vital for memory: re-evaluating diencephalic inputs for amnesia. Brain. 2009;132(Pt 9):2372–84.

168. Preston AR, Eichenbaum H. Interplay of hippocampus and prefrontal cortex in memory. Curr Biol. 2013;23(17):R764–73.

169. Buckely MI, Mitchell AS. Retrosplenial cortical contributions to anterograde and retrograde memory in the monkey. Cereb Cortex. 2016;26(6):2905–18.

170. Falkner AL, Grosenick L, Davidson TJ, Deisseroth K, Lin D. Hypothalamic control of male aggression-seeking behavior. Nat Neurosci. 2016;19(4):596–604.

171. Ryan TJ, Roy DS, Pignatelli M, Arons A, Tonegawa S. Memory. Engram cells retain memory under retrograde amnesia. Science. 2015;348(6238):1007–13.

172. Ramirez S, Liu X, Lin PA, Suh J, Pignatelli M, Redondo RL, et al. Creating a false memory in the hippocampus. Science. 2013;341(6144):387–91.

173. Lux S, Bindrich VN, Markowitch HJ, Fink GR. Medial temporal lobe activation during autobiographical context memory retrieval of time and place and its dependency upon recency. Neurocase. 2015;21(1):23–32.

174. Tsanov M. Septo-hippocampal signal processing: breaking the code. Prog Brain Res. 2015;219:103–20.

175. Vertes RP. Major diencephalic inputs to the hippocampus: supramammillary nucleus and reuniens nuclei. Circuity and function. Prog Brain Res. 2015;219:121–44.

176. Dalrymple-Alford JC, Harland B, Loukavenko EA, Perry B, Mercer S, Collings DA, et al. Anterior thalamic nuclei lesions and recovery of function: relevance to cognitive thalamic. Neurosci Biobehav Rev. 2015;54:145–60.

177. Jankowski MM, Ronnvist KC, Tsianov M, Vann SD, Wright NF, Enrich JC, et al. The anterior thalamus provides a subcortical circuit supporting memory and spatial navigation. Front Syst Neurosci. 2013;7:45.

178. Bubb EJ, Kinnavane L, Aggleton JP. Hippocampal–diencephalic–cingulate networks for memory and emotion: an anatomical guide. Brain Neurosci Adv. 2017. https://doi.org/10.1177/2398212817723443.

179. Mathiasen ML, Dillingham CM, Kinnavane L, Powell AL, Aggleton JP. Asymmetric cross-hemispheric connections link the rat anterior thalamic nuclei with the cortex and hippocampal formation. Neurosci. 2017;349:128–43.

180. Tsanov M, O’Mara SM. Decoding signal processing in thalamo–hippocampal circuits: implications for theories of memory and spatial processing. Brain Res. 2015;1621:368–79.

181. Dillingham CM, Frizzati A, Nelson AJ, Vann SD. How do mammillary body inputs contribute to anterior thalamic function? Neurosci Biobehav Rev. 2015;54:108–19.

182. Cassel JC, Pereira de Vasconcelos A, Loureiro M, Cholvin T, Dalrymple-Alford JC, Vertes RP. The reuniens and rhomboid nuclei: neuroanatomy, electrophysiological characteristics and behavioral implications. Prog Neurobiol. 2013;111:34–52.

183. Loureiro M, Cholvin T, Lopez J, Merienne N, Lateral A, Cosquer B, et al. The ventral midline thalamus (reuniens and rhomboid nuclei) contributes to the persistence of spatial memory in rats. J Neurosci. 2012;32(29):9947–59.

184. Duan AR, Varela C, Zhang Y, Shen Y, Xiong L, Wilson MA, et al. Delta frequency optogenetic stimulation of the thalamic nucleus reuniens is sufficient to produce working memory deficits: relevance to schizophrenia. Biol Psychiatry. 2015;77(12):1098–107.

185. Shen Y, Campbell RE, Cote DC, Paquet ME. Challenges for therapeutic applications of opsin-based optogenetic tools in humans. Front Neur Circuits. 2020;14:41.

186. Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317–34.

187. Ordaz JD, Wu W, Xu XM. Optogenetics and its application in neural degeneration and regeneration. Neural Regen Res. 2017;12(8):1197–209.

188. Jolle C, Deglon N, Pothoul C, Boulanger-Sore AK, Pellerin L. Development of efficient AAV2/DJ-based viral vectors to selectively downregulate the expression of neuronal or astrocytic target proteins in the rat central nervous system. Front Mol Neurosci. 2019;12:201.

189. Hardcastle N, Bouls NM, Federici TA. AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials. Expert Opin Biol Ther. 2018;18(3):293–307.

190. Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019;102(1):263.

191. Bonin RP, Wang F, Desrochers-Couture M, Ga Secka A, Boulanger ME, Cote DC, et al. Epidural optogenetics for controlled analgesia. Mol Pain. 2016. https://doi.org/10.1177/1744806916629051.

192. Mickle AD, Won SM, Noh KN, Yoon J, Meacham KW, Xue Y, et al. A wireless closed-loop system for optogenetic peripheral neuromodulation. Nature. 2019;565(7739):361–5.

193. Bartel M, Schaffer D, Buning H. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front Microbiol. 2012;2:204.

194. Meadows AS, Pineda RJ, Goodchild L, Bobo TF, Hu T. Threshold for pre-existing antibody levels limiting transduction efficiency of systemic rAAV9 gene delivery: relevance for translation. Mol Ther Methods Clin Dev. 2019;13:453–62.

195. Nidetz NF, McGee MC, Tse LV, Li C, Cong L, Li Y, et al. Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery. Pharmacol Ther. 2020;207:107453.

196. Han X, Qian X, Bernstein JG, Zhou HH, Franzesi GT, Stern P, et al. Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. Neuron. 2009;62(2):191–8.

197. Han X, Chow BY, Zhou H, Klapoetke NC, Chuong A, Rajmehr R, et al. A high-light sensitivity optical neural senser: development and application to optogenetic control of non-human primate cortex. Front Syst Neurosci. 2011;5:p18.

198. Sahel JA, Boulanger-Scema MMA, Pagot C, Arieo A, Gallupi F, Martel JN, et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med. 2021;27(7):1223–9.